JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Article

New Aromatic Compounds from the Fruiting Body of Sparassis crispa (Wulf.) and Their Inhibitory Activities on PCSK9 mRNA Expression

Sunghee Bang, Hee-Sung Chae, Changyeol Lee, Hyun Gyu Choi, JiYoung Ryu, Wei Li, Hanna Lee, Gil-Saeng Jeong, Young-Won Chin, and Sang Hee Shim

J. Agric. Food Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.jafc.7b02657 • Publication Date (Web): 09 Jul 2017

ACS Publications

Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY

Journal of Agricultural and Food Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

New Aromatic Compounds from the Fruiting Body of *Sparassis crispa* (Wulf.) and Their Inhibitory Activities on PCSK9 mRNA Expression

Sunghee Bang,[†] Hee-Sung Chae,[‡] Changyeol Lee,[†] Hyun Gyu Choi,[†] JiYoung Ryu,[†] Wei Li,[§] Hanna Lee,[#] Gil-Saeng Jeong,[⊥] Young-Won Chin,[‡] and Sang Hee Shim[†,*]



New Aromatic Compounds from the Fruiting Body of *Sparassis crispa* (Wulf.) and Their Inhibitory Activities on PCSK9 mRNA Expression

Sunghee Bang,[†] Hee-Sung Chae,[‡] Changyeol Lee,[†] Hyun Gyu Choi,[†] Jiyoung Ryu,[†] Wei Li,[§] Hanna Lee,[#] Gil-Saeng Jeong,[⊥] Young-Won Chin,[‡] and Sang Hee Shim[†,*]

[†]College of Pharmacy, Duksung Women's University, Samyang-ro, Dobong-gu, Seoul 01369, Republic of Korea; E-mails: scbsh4331@hanmail.net (SH. Bang), jaber29@naver.com (CY. Lee), chg---@hanmail.net (H.G. Choi), ryuji@hanmail.net (J. Ryu).

[‡]College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University-Seoul, 32, Dongguk-lo, Goyang-si, Gyeonggi-do 10326, Republic of Korea; E-mails: chaeheesung83@gmail.com (H.-S. Chae), f2744@dongguk.edu (Y.-W. Chin).

[§]KM Application Center, Korea Institute of Oriental Medicine, Daegu, Republic of Korea; E-mail: liwei1986@kiom.re.kr (W. Li).

[#]National Development Institute of Korean Medicine, Gyeongsan 38540, Republic of Korea; E-mail: iiihanna@nikom.or.kr (HN. Lee).

[⊥]College of Pharmacy, Keimyung University, Daegu 42601, Republic of Korea; E-mail: gsjeong@kmu.ac.kr (G.-S. Jeong).

* Corresponding author (Tel: +82 2 901 8774; Fax: +82 2 901 8386: E-mail: sangheeshim@duksung.ac.kr)

ABSTRACT

Successive chromatography of EtOAc-soluble extracts of the fruiting body of *Sparassis crispa* (Wulf.) resulted in isolation of four new aromatic compounds, sparoside A, **1**, and sparalides A-C, **3**-**5**, two new naturally-occurring compounds, **2** and **6**, in addition to eight known compounds, **7**-**14**. The chemical structures were determined by interpretation of NMR and MS spectroscopic data. Extract, solvents-soluble fractions of the extract, and all the pure compounds isolated from the fractions were subjected to mRNA expression assay for proprotein convertase subtilisin/kexin type 9 (PCSK9). Among them, sparoside A, **1**, hanabiratakelide A, **8**, adenosine, **11**, and 5α,6α-epoxy-(22*E*,24*R*)-ergosta-8(14),22-diene-3β,7β-diol, **14**, exhibited potent inhibitory activities on PCSK9 mRNA expression with IC_{50} values of 20.07, 7.18, 18.46 and 8.23 μM, respectively (berberine, positive control, IC_{50} = 8.04 μM), suggesting that compounds **1**, **8**, **11**, and **14** are suitable for use in supplements to the statins for hyperlipidemia treatments.

KEYWORDS: *Sparassis crispa*, proprotein convertase subtilisin/kexin type 9 (PCSK9), phthalide, sparoside A.

INTRODUCTION

Sparassis crispa (Wulf.) is an edible/medicinal mushroom belonging to the family of Sparassidaceae and is called "cauliflower mushroom" due to its appearance. The mushroom, which mostly grows on the stubs of coniferous trees, is distributed throughout northern temperature zones of the world.[1] The fruiting bodies of *S. crispa* produce various bioactive substances, including β-glucan,[2] benzoate derivatives,[3] sesquiterpenoids,[4] and maleic acid derivatives.[5] In particular, β-glucan is a major constituent, present in more than 40% of *S. crispa*. They have been demonstrated to show a variety of pharmacological activities, including antitumor,[6-8] hematopoietic response-enhancing,[9] wound healing,[10] antimetastatic, antihypertensive, and antidiabetic effects.[11]

Proprotein convertase subtilisi/kexin type 9 (PCSK9) is noted to interfere with the function of low-density lipoprotein receptor (LDLR) on the liver cell surface that transport LDL-cholesterol (LDL-C) into the liver for metabolism, leading to high levels of LDL-C. Thus, PCSK9 inhibitor was proposed to be a new LDL-C lowering agent. When PCSK9 inhibitor was used in combination with a statin, known as a HMG-CoA reductase inhibitor, it has been shown to dramatically lower LDL-C levels by up to 60%. Therefore, PCSK9 inhibitor has recently emerged as a new strategy to treat hyperlipidemia. To date two PCSK9 inhibitors (evolocumab and alirocumab) have been approved by FDA to treat familial hypercholesterolemia and several PCSK9 inhibitors are currently under clinical trial.[12] In addition, several natural compounds such as berberine and curcumin have been reported to inhibit PCSK9 mRNA expression.[13] For these reasons, more investigation is required to discover new PCSK9 inhibitors, which could be good supplements to statin treatment due to their effects on PCSK9 mRNA.

The extracts of the cauliflower mushroom were reported to exhibit antihypertensive and antidiabetic activities related to hyperlipidemia. To our knowledge there are no reports on effects of cauliflower mushroom and its constituents on PCSK9 mRNA expression. We therefore examined the effects of the extracts and its pure compounds on PCSK9 mRNA expression to see if their hypocholesterolemic effects could be partly explained by additional effects on the PCSK9 mRNA expression. We found that some compounds from the cauliflower mushroom extracts inhibit the PCSK9 mRNA expression. Therefore, we herein report the isolation of compounds, their structural determination, and their PCSK9 inhibitory activities from the extract of *S. crispa*.

MATERIALS AND METHODS

General experimental procedures.

The HRESIMS data were obtained on a UHR ESI Q-TOF mass spectrometer (Bruker, Billerica, MA). The NMR spectra were acquired with a 300 Ultra shield spectrometer (^{1}H: 300 MHz/^{13}C: 75 MHz) (Bruker), a NMR systems 500 MHz (^{1}H: 500 MHz/^{13}C: 125 MHz) (Varian, Palo Alto, CA), and a DD2 700 spectrometer (^{1}H: 700 MHz/^{13}C: 175 MHz) (Agilent Technologies, Santa Clara, CA) using the solvent signals (δ_H 2.50/δ_C 39.51 for DMSO-d_6; δ_H 3.31/δ_C 49.15 for CD_3OD) (Cambridge Isotope Laboratories, Inc., Tewksbury, MA) as internal standards; chemical shifts are indicated as δ values. The analytical high performance liquid chromatography (HPLC) was carried out on a 1260 infinity HPLC system (Agilent Technologies) supplied with a G1311C quaternary pump, a G1329B autosampler, a G1315D PDA detector, and a G1316A oven for column. The column used was a 150 mm x 4.6 mm i.d.,

5 μm, ZORBAX SB-C18 (Agilent Technologies). Semi-preparative HPLC was operated on a 600 controller (Waters, Milford, MA) with a 996 PDA detector using the column ZORBAX SB-C18 (250 mm x 21.2 mm i.d., 5 μm, Agilent Technologies). Column chromatography was operated over silica gel 60 (70-230 mesh) (Merck, Darmstadt, Germany). Silica gel 60 F_{254} and RP-18 F_{254S} plates (Merck) were used for analysis by thin layer chromatography (TLC) under detection of UV and 10% H_2SO_4 reagent to visualize the compounds. Analytical grade of solvents were used for the whole experiments.

Plant Material.

Dried fruiting bodies of *S.crispa* were provided by Gyeongshin Bio Co. (Euiwang, South Korea) in August 2016. This sample was botanically identified by the corresponding author (S.H. Shim). A voucher was deposited at the pharmacognosy laboratory of College of Pharmacy, Duksung Women's University (specimen No.: NPC-16-08).

Extraction and Isolation.

Dried fruiting bodies of *S. crispa* (1 kg) were extracted with 100% MeOH (3.0 L) under reflux three times to afford 153.0 g of the extracts. The extracts were suspended in distilled water (1.0 L) and partitioned using *n*-hexane (3 x 1.0 L), CH_2Cl_2 (3 x 1.0 L), EtOAc (3 x 1.0 L), and *n*-BuOH (3 x 1.0 L) consecutively, yielding *n*-hexane (17.6 g), CH_2Cl_2 (2.7 g), EtOAc (9.8 g), *n*-BuOH (15.0 g), and H_2O (107.9 g) layers, respectively. The EtOAc-soluble layer (9.8 g) was set apart by vacuum liquid chromatography (VLC) (40 x 9 cm) over silica gel

using gradient solvents of *n*-hexane/EtOAc/MeOH (10:1:0, 2.5:1:0, 1.5:1:0, 1:1:0.2; each 5 L), $CHCl_3$/MeOH/H_2O (10:1:0, 5:1:0.1; each 5 L), and 100% MeOH (3 L) to obtain seven fractions (Fr. E1 ~ Fr. E7). Silica gel column chromatography was employed to fraction E2 with the elution of *n*-hexane/acetone gradient solvents (20:1, 15:1; each 0.2 L) to afford compound **2** (8.6 mg). Fraction E4 (1.4 g) was fractionated on silica gel column chromatography (15 x 8 cm) with gradient solvents of $CHCl_3$/acetone (65:1, 20:1, 10:1, 7:1; each 1 L) and 100% MeOH (1 L) to afford six fractions (Fr. E4-1 ~ Fr. E4-6). Fraction E4-1 was further purified with reversed-phase HPLC using a H_2O/acetonirile (60:40 → 45:55, v/v) gradient to yield compounds **12** (15 mg), **13** (18.5 mg), and **14** (1.5 mg). Compounds **1** (2.4 mg), **5** (2.9 mg), **6** (1.7 mg), **7** (1.8 mg), **8** (5.6 mg), **9** (7.3 mg), and **10** (4.1 mg) were obtained from fraction E5 using reversed-phase HPLC with a gradient of H_2O/MeOH (80:20 → 0:100, v/v). Fraction E6 was subjected to reversed-phase HPLC with gradient solvents of H_2O/MeOH (95:5 → 50:50, v/v) to furnish compounds **3** (13.0 mg), **4** (6.5 mg), and **11** (2.9 mg).

*Sparoside A (2-hydroxy-3-methoxy-6-methyl benzoic acid methyl ester 4-O-α-D-riboside, **1**)*.

Yellowish amorphous solid; (+) HRESIMS *m/z* 367.1003 $[M + Na]^+$ (calcd for $C_{15}H_{20}NaO_9$, 367.1000); ^1H and ^{13}C NMR (Table 1); HMBC correlations (CD_3OD, H → C) H-5 → C-1, C-3, C-4, and CH_3; H-1' → C-4, C-2', C-3', and C-4'; H-2' → C-1'; H-3' → C-1', C-2', C-4', and C-5'; H_2-5' → C-3' and C-4'; CH_3 → C-5 and C-6; OCH_3 → C-3; $COOCH_3$ → $COOCH_3$.

126 *Sparalide A (5-methoxy-phthalide 7-O-α-D-riboside, **3**).*

127 White amorphous powder; (+) HRESIMS *m/z* 335.0738 $[M + Na]^+$ (calcd for
128 $C_{14}H_{16}NaO_8$, 335.0737); ^1H and ^{13}C NMR (Table 1); HMBC correlations (DMSO-d_6, H → C)
129 H-3 → C-1, C-3a, C-4, C-5, and C-7a; H-4 → C-3, C-5, C-6, C-7, and C-7a; H-6 → C-1, C-4,
130 C-5, C-7, and C-7a; H-1' → C-3', C-4', and C-7'; H-3' → C-1'; H-4' → C-3'; H_2-5' → C-3' and
131 C-4'; OCH_3 → C-5.

132

133 *Sparalide B (6-methoxy-4,5,7-trihydroxy phthalide, **4**).*

134 Yellow amorphous solid; (+) HRESIMS *m/z* 235.0212 $[M + Na]^+$ (calcd for $C_9H_8NaO_6$,
135 235.0213); ^1H and ^{13}C NMR (Table 1); HMBC correlations (DMSO-d_6, H → C) H_2-3 → C-1,
136 C-3a, C-4, C-5, C-7, and C-7a; $OC\underline{H}_3$ → C-6.

137

138 *Sparalide C (5,6-dihydroxy-7-methoxy phthalide, **5**).*

139 Colorless amorphous solid; (+) HRESIMS *m/z* 219.0268 $[M + Na]^+$ (calcd for
140 $C_9H_8NaO_5$, 219.0264); ^1H and ^{13}C NMR (Table 1); HMBC correlations (CD_3OD, H → C)
141 H_2-3 → C-1, C-3a, C-4, C-5, and C-7a; H-4 → C-3, C-5, C-6, and C-7a; $OC\underline{H}_3$ → C-7.

142

143 **Acid hydrolysis of compounds 1 and 3.**

144 Each 1 mg of compounds **1** and **3** was hydrolyzed with 1N HCl (1 mL) at 80 °C for 2 h
145 to afford aglycone and sugar moieties. The reaction mixtures were extracted with EtOAc to

separate a sugar moiety-containing aqueous fraction from the aglycone-containing fraction. The aqueous fraction was evaporated and then analyzed on silica gel TLC plates with a gradient of acetone/H_2O for the comparison with authentic D-ribose and L-ribose (Sigma-Aldrich, St. Louis, MO).

Determination of absolute configuration of ribose.

To determine absolute configuration of the ribose in compounds **1** and **3**, derivatives of the sugar moieties were analyzed.[14] Acid hydrolysis of each compound afforded aglycone and sugar moieties. The sugar moieties (each 0.5 mg) were dissolved in pyridine (100 μL), supplemented with L-cysteine methyl ester hydrochloride (0.5 mg), and placed at 60 °C for 1 h for reaction. Ten microliters of *o*-tolyl isothiocyanate was then added to the mixture to allow for a reaction at 60 °C for 1 h. Each of the mixture was evaporated and subjected to reverse-phase HPLC for analysis; ZORBAX SB-C18 column (Agilent Technologies, 250 x 4.6 mm i.d., 5 μm); column temperature 35 °C; mobile phase H_2O/acetonitrile (75:25, v/v) for 30 min; flow rate 0.8 mL/min; detection wavelength at 250 nm. Both authentic D-ribose and L-ribose were reacted in the same manner as described above. The absolute configuration of ribose in compounds **1** and **3** was assigned by comparing their retention times with those of the authentic derivatives (t_R: D-ribose derivative 12.68 min, L-ribose derivative 8.20 min).

PCSK9 mRNA Expression Assay.

RNA extraction procedure provided by the TRIzol (Life Technologies, Carlsbad, CA)

was employed for total RNA extraction. In brief, cDNA was prepared by adding reverse transcriptase (200 U) and oligo-dT primer (500 ng) to total RNA (1 μg) in 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM $MgCl_2$, 10 mM DTT, and 1 mM dNTPs at 42 °C for 1 h. Incubation of the solution at 70 °C for 15 min terminated the reaction and an aliquot of the cDNA mixture (1 μL) was adopted for enzyme amplification. Polymerase chain reactions were conducted by cDNA (1 μL), master mix (9 μL) containing iQ SYBR Green Supermix (Bio-Rad, Hercules, CA), 5 pmol of forward primer, and 5 pmol of reverse primer using a CFX384 Real-Time PCR System (Bio-Rad) with the following conditions: 3 min at 95 °C, subsequently 40 cycles for 10 s at 95 °C, then 30 s at 55 °C, and finally plate reading. The fluorescence which was generated using SYBR Green I DNA dye was quantified in the course of the annealing. Specificity of the amplification was ascertained through a melting curve analysis. CFX Manager Software (Bio-Rad) was used for acquisition of data, which were presented as the cycle threshold (C_T). Then, relative abundance of an interesting gene was standardized to that of glyceraldehyde 3-phosphate dehydrogenase ($\Delta\Delta C_T$). The $2^{-(\Delta\Delta CT)}$ method[15] was employed for calculation of mRNA abundance of the sample. Specific primer sets used in this study were as follows (5′–3′): GAPDH: GAAGGTGAAGGTCGGAGTCA (forward), AATGAAGGGGTCATTGATGG (reverse), PCSK9: GGGCATTTCACCATTCAAAC (forward), TCCAGAAAGCTAAGCCTCCA (reverse). Custom-synthesized gene-specific primers were provided by Bioneer (Daejeon, Korea).

Statistical Analyses.

Data were expressed as the mean ± SEM. Analysis of variance (ANOVA) determined

the level of statistical significance and Dunnett's *t*-test was used for multiple comparison procedures. *P* values (calculated probability) less than 0.05 were regarded to be significant.

RESULTS AND DISCUSSION

Structural Elucidation.

A series of chromatographic methods carried out on the extract of *S. crispa* led to the isolation of fourteen compounds, which include four new aromatic compounds, **1** and **3**-**5**, two new naturally-occurring compounds, **2** and **6**, and eight known compounds, **7**-**14** (Figure 1).

The known compounds were identified to be methyl 2,4-dihydroxy-3-methoxy-6-methylbenzoate, **2**,[16] 5-hydroxy-7-methoxyphthalide, **6**,[17] 5-methoxy-7-hydroxyphthalide, **7**,[17] hanabiratakelide A, **8**,[18] nicotinamide, **9**,[19] 5′-deoxy-5′-methylthioadenosine, **10**,[20] adenosine, **11**,[21] ergosterol, **12**,[22] ergosterol peroxide, **13**,[23] and 5α,6α-epoxy-(22*E*,24*R*)-ergosta-8(14),22-diene-3β,7β-diol, **14**[24] by comparing their NMR and MS data with those in the reference. Of these, although compounds **2** and **6** have been reported as synthetic intermediates, they have been reported for the first time in nature in this study.

Compound **1** was obtained as a yellowish amorphous solid. Positive HRESIMS suggested its molecular formula to be $C_{15}H_{20}O_9$. The ^{1}H NMR spectrum of **1** displayed an aromatic proton at δ_H 6.66 (1H, s, H-5), one sugar unit at δ_H 5.73-3.65, two methoxyl groups at δ_H 3.93 (3H, s, COO$\underline{C}H_3$) and 3.85 (3H, s, 3-OCH_3), and methyl group at δ_H 2.43 (3H, s, 6-CH_3). The ^{13}C NMR spectrum of **1** suggested existence of a carbonyl group (δ_C 172.81), six

aromatic carbons (δ_C 156.45, 154.57, 137.40, 137.22, 112.34, and 111.09), one sugar unit (δ_C 102.64, 88.46, 73.82, 71.23, and 63.30), two methoxyl groups (δ_C 61.63 and 52.68), and a methyl group (δ_C 23.28). One sugar unit was confirmed to consist of a ribose by ^{1}H and ^{13}C NMR data, which was further supported by chemical reaction. Acid hydrolysis of **1** followed by TLC with authentic ribose supported that the sugar was ribose. Moreover, the 4.4 Hz of coupling constant for the anomeric proton at δ_H 5.73 suggested an α-configuration. HMBC correlation of the methoxyl protons at δ_H 3.93 with the carbonyl carbon at δ_C 172.81 indicated that the methyl carboxylate was attached to the aromatic ring. The positions of the methoxyl, methyl group and ribose at the aromatic ring were assigned by analysis of the HMBC spectrum. HMBC correlations of the methoxyl protons at δ_H 3.85 with the aromatic carbon at δ_C 137.22 and the anomeric proton at δ_H 5.73 with the aromatic carbon at δ_C 154.57 allowed for the assignment of the carbons bearing the methoxyl group and the ribose. HMBC correlation of the methyl protons at δ_H 2.43 with the aromatic methine carbon at δ_C 112.34 and the non-protonated aromatic carbon at δ_C 137.40 and the aromatic methine proton at δ_H 6.66 with the carbons at δ_C 111.09, 137.22, and 154.57 indicated the methyl, the methyl carboxylate, the methoxyl, and the ribose were attached to the C-6, C-1, C-3, and C-4 positions, respectively. Determination of the absolute configuration of the ribose was conducted by comparing retention time of L-cysteine methyl ester and *o*-tolyl isothiocyanate derivative of acid-hydrolysate with those for authentic D-/L- ribose derivatives in HPLC-UV. The derivatives of the authentic D-ribose and L-ribose eluted at t_R 12.68 (D-ribose) and 8.20 (L-ribose) min, respectively on the isocratic HPLC. Since the derivative of compound **1** eluted at t_R 11.93 min, the ribose in **1** was confirmed to have D configuration. Thus, the structure of **1** was determined to be 2-hydroxy-3-methoxy-6-methyl benzoic acid methyl ester

4-*O*-*α*-D-riboside and was named as sparoside A.

Compound **3** was obtained as a white amorphous powder. Its positive HRESIMS data suggested the molecular formula to be $C_{14}H_{16}O_8$. The ^{1}H NMR spectrum displayed two aromatic methine protons at δ_H 6.82 (1H, s, H-4) and 6.81 (1H, s, H-6), an oxymethylene at δ_H 5.28 (2H, s, H-3), one sugar unit at δ_H 5.95-3.45 and a methoxyl group at δ_H 3.85 (3H, s, 5-OCH_3). The ^{13}C NMR spectrum of **3** suggested the presence of a carbonyl group (δ_C 168.89), six aromatic carbons (δ_C 166.11, 156.23, 151.68, 107.05, 102.59, and 100.49), one pentose moiety (δ_C 101.47, 87.99, 71.74, 69.77, and 61.48), an oxymethylene (δ_C 68.98), and a methoxyl carbon (δ_C 56.19). It was presumed to be bicyclic compound to meet seven unsaturations obtained from its molecular formula. The presence of an aromatic ring, an oxymethylene group, together with carboxyl carbon indicated that compound **3** has a phthalide skeleton, which has previously been reported in *S. crispa*. The pentose was presumed to be ribose, based on the carbon chemical shifts and proton resonances. The coupling constant (3.9 Hz) of the anomer proton suggested that the ribose was attached to the aglycone with an *α*-configuration. The presence of ribose was verified by the direct comparison of acid hydrolysate of **3** with commercially available authentic ribose. The HMBC correlations of the oxymethylene at δ_H 5.28 with the carboxyl carbon (δ_C 168.89) and the aromatic carbon (δ_C 151.68 and 107.05) supported the idea that **3** had a *γ*-lactonylated aromatic compound, known as a phthalide. The singlet aromatic methine protons suggested the methoxyl group and the ribose moiety were not attached to the adjacent carbon atoms of the aromatic ring. Their positions were confirmed by HMBC data. HMBC correlations of the anomeric proton (δ_H 5.95) with the carbon (δ_C 156.23) and methoxyl protons (δ_H 3.85) with the carbon (δ_C 166.11) indicated that the ribose and the methoxyl groups were attached to

carbons at δ_C 156.23 and 166.11, respectively. HMBC correlations of the H-4 methine proton at δ_H 6.82 of the phthalide with the methoxylated carbon (δ_C 166.11), another aromatic methine carbon (δ_C 102.59), and the non-protonated aromatic carbon (δ_C 107.05) indicated that the methoxyl group and the ribose were attached to C-5 and C-7, respectively. Thus a planar structure could be established. Assignment of the absolute configuration of ribose was conducted as described above. Since the retention time of the ribose derivative of acid hydrolysate for **3** was same as that for the D-ribose derivative, structure of compound **3** was determined as 5-methoxy-phthalide 7-*O*-*α*-D-riboside, named sparalide A.

Compound **4** was obtained as a yellow amorphous solid, in which its molecular formula was established as $C_9H_8O_6$ on the basis of positive HRESIMS. In its ^{1}H NMR spectrum, one oxymethylene and one methoxyl signal appeared at δ_H 5.09 (2H, s, H-3) and 3.79 (3H, s, 6-OCH_3), respectively. Six aromatic carbons (δ_C 141.94, 139.30, 139.19, 135.44, 124.99, and 106.25), an oxymethylene carbon (δ_C 66.79), and a carbonyl group (δ_C 168.90) shown in the ^{13}C NMR spectrum suggested that **4** had a phthalide skeleton, similar to compound **3**. The position of the methoxyl group was assigned to be attached to C-6 on the ground that the methoxyl protons (δ_H 3.79) showed HMBC correlations with C-6 (δ_C 139.31) while the oxymethylene protons (δ_H 5.09) showed HMBC correlations with C-7 (δ_C 141.94), C-5 (δ_C 139.19), C-4 (δ_C 135.44), C-3a (δ_C 124.99), and C-7a (δ_C 106.25) (Figure 2). $^4J_{CH}$ HMBC correlations between H_2-3 and C-5 and C-7 in addition to $^3J_{CH}$ HMBC correlations between the H_2-3 and C-4 ascertained that the methoxyl group was attached to C-6 rather than C-4, C-5 or C-7. From these evidences, the structure of **4** was determined to be 6-methoxy-4,5,7-trihydroxy phthalide, named sparalide B.

Compound **5** was a colorless amorphous solid and the molecular formula was confirmed

to be $C_9H_8O_5$ by positive HRESIMS. The ^{1}H NMR spectrum of **5** showed an aromatic proton at δ_H 6.68 (1H, s, H-4), an oxymethylene at δ_H 5.15 (2H, s, H-3), and a methoxyl group at δ_H 4.01 (3H, s, 7-OCH_3). Its ^{13}C NMR spectrum exhibited six aromatic carbons (δ_C 155.49, 147.44, 142.32, 139.62, 109.50, and 104.67), an oxymethylene carbon (δ_C 70.46), a carboxyl carbon (δ_C 172.14), and a methoxyl carbon (δ_C 62.65). The ^{1}H and ^{13}C NMR data presented similarities to those for **4**, except for an additional aromatic proton at δ_H 6.68. Thus, it was assumed that two hydroxyl groups and a methoxyl group were attached to the aromatic ring of the phthalide skeleton, which was also supported by the observation of HR-ESI-MS. The positions of the aromatic methine carbon and the methoxylated carbon were assigned to be C-4 and C-7, respectively, supported by HMBC correlations of H-4 (δ_H 6.68) with C-3 (δ_C 70.46), C-5 (δ_C 155.49), C-6 (δ_C 139.62), C-3a (δ_C 142.32), and C-7a (δ_C 109.50) and the methoxyl proton (δ_H 4.01) with C-7 (δ_C 147.44) (Figure 2). Using these data, the structure of **5** was established to be 5,6-dihydroxy-7-methoxy phthalide, named sparalide C.

Evaluation of PCSK9 mRNA expression.

The MeOH extract and polarity-based solvent-soluble layers of *S. crispa* were tested on inhibitory activity of PCSK9 mRNA expression using a HepG2 cells. The EtOAc-soluble layer showed the most potent inhibitory activities at 10 μg/mL, which prompted us to elucidate the active compounds from the EtOAc-soluble layer (Figure 3). Bioactivity-guided fractionation led to isolation of fourteen compounds, **1**-**14**, from this layer. All the isolated compounds were assessed for their PCSK9 mRNA expression. The results demonstrated that compounds **1**, **8**, **11**, and **14** were found to potentially inhibit PCSK9 mRNA expression with

301 IC_{50} values of 20.07, 7.18, 18.46, and 8.23 μM, respectively, at the concentration of 20 μM,
302 whereas the IC_{50} of berberine, positive control, was 8.04 μM at the same concentration as the
303 isolated compounds. When compared with the positive control, compound **8**
304 (hanabiratakelide A) was found to be a stronger PCKS9 inhibitor than berberine, which is
305 known to be one of the most potent PCSK9 inhibitors in nature far.

306 Concerning the structure-activity relationship, the results showed that 4,5,6-trioxygenated
307 pattern in phthalide moiety seemed to be important for the PCSK9 inhibitory activity rather
308 than di-oxygenation or tetra-oxygenation pattern as shown in compound **8**. In the case of
309 simple benzoic acid derivatives (compounds **1** and **2**), ribose moiety seemed to be important
310 in the activity as shown for compound **1**. The ribose moiety seemed also to play an important
311 role in adenosine derivatives (compounds **10** and **11**), where the OH group at C-5 of ribose
312 moiety seemed to be effective rather than SCH_3. In the case of ergosterol derivatives, the OH
313 group and epoxide substituents on the B ring seemed to be more effective than when they had
314 endoperoxide or diene system.

315 The results suggest that hanabiratakelide A, **8**, and 5α,6α-epoxy-(22*E*,24*R*)-ergosta-
316 8(14),22-diene-3β,7β-diol, **14**, as well as the extract of *S. crispa* could be good supplements
317 to statins for the treatment of hyperlipidemia. Moreover, further studies regarding the
318 mechanistic and *in vivo* efficacies for compounds **8** and **14** might be required.

319 **Supporting Information**

320 The Supporting Information is available free of charge on the ACS Publications
321 website at DOI: .

322 NMR and HRMS spectra of compounds **1** and **3**-**5** (PDF)

ACKNOWLEDGMENT

This study was supported by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries(IPET) through High Value-added Food Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA, 116001-3) and also supported by the National Research Foundation (NRF) of Korea (Grant No. NRF-2015R1D1A1A01057914 and NRF-2016R1A6A1A03007648).

REFERENCES

(1) Imazeki, R.; Hongo, T. *Colored Illustrations of Mushrooms of Japan*, 2th ed.; Hoikusha Publishers: Osaka, Japan, **1989**; pp 109.

(2) Tada, R.; Harada, T.; Nagi-Miura, N.; Adachi, Y.; Nakajima, M.; Yadomae, T.; Ohno, N. NMR characterization of the structure of a β-(1→3)-D-glucan isolate from cultured fruit bodies of *Sparassis crispa*. *Carbohydr. Res.* **2007**, *342*, 2611-2618.

(3) Woodward, S.; Sultan, H. Y.; Barrett, D. K.; Pearce, R. B. Two new antifungal metabolites produced by *Sparassis crispa* in culture and in decayed trees. *J. Gen. Microbiol.* **1993**, *139*, 153-159.

(4) Kodani, S.; Hayashi, K.; Hashimoto, M.; Kimura, T.; Dombo, M.; Kawagishi, H. New sesquiterpenoid from the mushroom *Sparassis crispa*. *Biosci., Biotechnol., Biochem.* **2009**, *73*, 228-229.

(5) Kawagishi, H.; Hayashi, K.; Tokuyama, S.; Hashimoto, N.; Kimura, T.; Dombo, M. Novel bioactive compound from the *Sparassis crispa* mushroom. *Biosci., Biotechnol., Biochem*. **2007**, *71*, 1804-1806.

(6) Ohno, N.; Miura, N. N.; Nakajima, M.; Yadomae, T. Antitumor 1,3-β-glucan from cultured fruit body of *Sparassis crispa*. *Biol. Pharm. Bull.* **2000**, *23*, 866-872.

(7) Ohno, N.; Nameda, S.; Harada, T.; Miura, N. N.; Adachi, Y.; Nakajima, M.; Yoshida, K.; Yoshida, H.; Yadomae, T. Immunomodulating activity of a β-glucan preparation, SCG, extracted from a culinary-medicinal mushroom, *Sparassis crispa* Wulf.:Fr. (aphyllophoromycetideae), and application to cancer patients. *Int. J. Med. Mushrooms*

2003, *5*, 359-368.

(8) Yamamoto, K.; Kimura, T.; Sugitachi, A.; Matsuura, N. Anti-angiogenic and anti-metastatic effects of β-1,3-D-glucan purified from hanabiratake, *Sparassis crispa*. *Biol. Pharm. Bull.* **2009**, *32*, 259-263.

(9) Harada, T.; Miura, N.; Adachi, Y.; Nakajima, M.; Yadomae, T.; Ohno, N. Effect of SCG, 1, 3-β-D-glucan from *Sparassis crispa* on the hematopoietic response in cyclophosphamide induced leukopenia mice. *Biol. Pharm. Bull.* **2002**, *25*, 931-939.

(10) Kwon, A. H.; Qiu, Z.; Hashimoto, M.; Yamamoto, K.; Kimura, T. Effects of medicinal mushroom (*Sparassis crispa*) on would healing in streptozotocin-induced diabetic rats. *Am. J. Surg.* **2009**, *197*, 503-509.

(11) Kimura, T. Natural products and biological activity of the pharmacologically active cauliflower mushroom *Sparassis crispa*. *BioMed Res. Int.* **2013**, *2013*, 982317.

(12) Zimmerman, M. P. How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control? *Am. Health Drug Benefits* **2015**, *8*, 436-442.

(13) Pagliaro, B.; Santolamazza, C.; Simonelli, F.; Rubattu, S. Phytochemical compounds and protection from cardiovascular diseases: a state of the art. *BioMed Res. Int.* **2015**, *2015*, 1-17.

(14) Tanaka, T.; Nakashima, T.; Ueda, T.; Tomii, K.; Kouno, I. Facile discrimination of aldose enantiomers by reversed-phase HPLC. *Chem. Pharm. Bull.* **2007**, *55*, 899-901.

(15) Livak, K. J.; Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta CT}$ method. *Methods* **2001**, *25*, 402-408.

(16) Elix, J. A.; Naidu, R.; Laundon, J. R. The structure and synthesis of 4-oxypannaric acid 2-methyl ester, a dibenzofuran from the lichen *Leproloma diffusum*. *Aust. J. Chem.***1994**, *47*, 703-714.

(17) El-Feraly, F. S.; Cheatham, S. F.; Mcchesney, J. D. Total synthesis of notholaenic acid. *J. Nat. Prod.* **1985**, *48*, 293-298.

(18) Yoshikawa, K.; Kokudo, N.; Hashimoto, T.; Yamamoto, K.; Inose, T.; Kimura, T. Novel phthalide compounds from *Sparassis crispa* (Hanabiratake), hanabiratakelide A-C, exhibiting anti-cancer related activity. *Biol. Pharm. Bull.* **2010**, *33*, 1355-1359.

(19) Shchepin, R. V.; Barskiy, D. A.; Mikhaylov, D. M.; Chekmenev, E. Y. Efficient synthesis of nicotinamide-1-^{15}N for ultrafast NMR hyperpolarization using parahydrogen. *Bioconjugate Chem.* **2016**, *27*, 878-882.

(20) Kehraus, S.; Gorzalka, S.; Hallmen, C.; Iqbal, J.; Muller, C. E.; Wright, A. D.; Wiese, M.; Konig, G. M. Novel amino acid derived natural products from the ascidian *Atriolum robustum*: Identification and pharmacological characterization of a unique adenosine derivative. *J. Med. Chem.* **2004**, *47*, 2243-2255.

(21) Chenon, M. T.; Pugmire, R. J.; Grant, D. M.; Panzica, R. P.; Townsend, L. B. A basic set of parameters for the investigation of tautomerism in purines established from carbon-13 magnetic resonance. *J. Am. Chem. Soc.* **1975**, *97*, 4627-4636.

(22) Nowak, R.; Drozd, M.; Mendyk, E.; Lemieszek, M.; Krakowiak, O.; Kisiel, W.; Rzeski, W.; Szewczyk, K. A new method for the isolation of ergosterol and peroxyergosterol as active compounds of *Hygrophoropsis aurantiaca* and in vitro antiproliferative activity of

isolated ergosterol peroxide. *Molecules* **2016**, *21*, 946-955.

(23) Krzyczkowski, W.; Malinowska, E.; Suchocki, P.; Kleps, J.; Olejnik, M.; Herold, F. Isolation and quantitative determination of ergosterol peroxide in various edible mushroom species. *Food Chem.* **2009**, *113*, 351-355.

(24) Ishizuka, T.; Yaoita, Y.; Kikuchi, M. Sterol constituents from the fruit bodies of *Grifola frondosa* (Fr.) S. F. Gray. *Chem. Pharm. Bull.* **1997**, *45*, 1756-1760.

399 Legends:

400 **Figure 1.** Structures of compounds **1**–**14** from *S. crispa*.

401 **Figure 2.** Key HMBC correlations of compounds **1**, **3**, **4**, and **5**.

402 **Figure 3.** Effect of (A) MeOH extracts and solvent-soluble fractions of *S. crispa* and (B)
403 isolated compounds from EtOAc-soluble fractions. Expression of PCSK9 mRNA was
404 assayed by qRT-PCR in cells treated with 10 μg/mL of solvent-soluble fractions and 20
405 μM of isolated compounds.

406

407

408

409

410

411

412

413

414

415 **Figure 1.**



416

417

418

419

420

421

422

423 **Figure 2.**



1



3



4



5

424

425

426

427

428

429

Figure 3.


A
PCSK9 mRNA relative expression
1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
Fraction (10 μg/ml) - MeOH Hexane CH_2Cl_2 EtOAc BuOH
B
PCSK9 mRNA relative expression
1.2
1
0.8
0.6
0.4
0.2
0
Compound (20 μM) - 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Ber

443 **Table 1.** The ^{1}H and ^{13}C NMR Data of Compounds **1** and **3**-**5**.

No.	**1**[a]		**3**[b]		**4**[b]		**5**[a]	
	δ_C	δ_H multi (*J* in Hz)	δ_C	δ_H multi (*J* in Hz)	δ_C	δ_H multi (*J* in Hz)	δ_C	δ_H multi (*J* in Hz)
1	111.09		168.89		168.90		172.14	
2	156.45							
3	137.22		68.98	5.28 s	66.79	5.09 s	70.46	5.15 s
3a			151.68		124.99		142.32	
4	154.57		100.49	6.82 s	135.44		104.67	6.68 s
5	112.34	6.66 s	166.11		139.19		155.49	
6	137.40		102.59	6.81 s	139.30		139.62	
7			156.23		141.94		147.44	
7a			107.05		106.25		109.50	
1'	102.64	5.73 d (4.4)	101.17	5.95 d (3.8)				
2'	73.82	4.32 dd (4.5, 6.4)	71.74	4.10 dd (4.0, 5.8)				
3'	71.23	4.10 dd (2.8, 6.5)	69.77	3.89 d (5.6)				
4'	88.46	4.16 m	87.99	4.00 dd (3.6, 5.8)				
5'	63.30	3.70 dd (3.4, 12) 3.65 dd (3.9, 12)	61.48	3.45 m				
OCH_3	61.63	3.85 s	56.19	3.85 s	61.60	3.79 s	62.65	4.01 s
CH_3	23.28	2.43 s						
$\underline{C}OOCH_3$	172.81							
$COO\underline{C}H_3$	52.68	3.93 s						

444 [a] Measured in CD_3OD

445 [b] Measured in DMSO-d_6